ACE2 and Sepsis: Most recently, Fagyas and colleagues evaluated serum ACE2 activity in severely- or critically-ill patients with COVID-19 and in non-COVID-19 severe sepsis patients and concluded that baseline ACE2 activity independently indicated COVID-19 severity and that higher ACE2 activity predicted a higher risk for 30-day mortality [34].